Benzylamine Derivatives
AssigneeKalvista Pharmaceuticals Limited
InventorsChristine Elizabeth Allan, Andrzej Roman Batt, Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Stephen John Pethen
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.
Claims21
A method of treating a disease or condition in which plasma kallikrein activity is implicated, comprising administration to a subject in need thereof a therapeutically effective amount of a compound of formula (I):
- wherein:
- V is C or N such that the aromatic ring containing V is phenyl or pyridine;
- R2 is absent when V is N;
- or, when present, R2 is H, alkyl, alkoxy, CN, halo or CF3;
- R1 and R3 are, independently, H, alkyl, alkoxy, CN, halo or CF3;
- W, X, Y and Z are, independently, C, N, O, or S, such that the ring containing W, X, Y and Z is a five-membered aromatic heterocycle;
- R5, R6 and R7 are, independently, absent, H, alkyl, halo, aryl, heteroaryl, or CF3;
- P is —C(R10)(R11)NH2;
- R8 and R9 are, independently, H or alkyl, or may together form a cycloalkyl ring;
- R10 and R11 are, independently, H or alkyl, or may together form a cycloalkyl ring or a cyclic ether;
- A is N-linked morpholine, aryl, or heteroaryl;
- and wherein
- alkyl is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10);
- alkyl is optionally substituted with 1 or 2 substituents which are, independently, (C1-C6)alkoxy, OH, CN, CF3, —COOR12, —CONR12R13, H(CH2)1-3CON(R12)(CH2)1-3—, fluoro and —NR12R13;
- cycloalkyl is a monocyclic saturated hydrocarbon of between 3 and 7 carbon atoms;
- wherein cycloalkyl is optionally substituted with a substituent which is alkyl, alkoxy or NR12R13;
- a cyclic ether is a monocyclic saturated hydrocarbon of between 4 and 7 carbon atoms, wherein one of the ring carbons is replaced by an oxygen atom;
- alkoxy is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6);
- alkoxy is optionally substituted with 1 or 2 substituents which are, independently, aryl, OH, CN, CF3, —COOR12, —CONR12R13, fluoro, or NR12R13;
- aryl is phenyl, biphenyl or naphthyl;
- aryl may be optionally substituted with 1, 2 or 3 substituents which are, independently, alkyl, alkoxy, OH, halo, CN, -morpholinyl, -piperidinyl, heteroaryl, arylb, —O-arylb, —(CH2)1-3-arylb, —(CH2)1-3-heteroaryl, —COOR12, —CONR12R13, —(CH2)1-3—NR14R15, CF3 and NR12R13;
- arylb is phenyl, biphenyl or naphthyl, which is optionally substituted with 1, 2 or 3 substituents which are, independently, alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, —COOR12, —CONR12R13, CF3, or NR12R13;
- heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members which are, independently, N, NR12, S or O;
- heteroaryl is optionally substituted with 1, 2 or 3 substituents which are, independently, alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, aryl, —(CH2)1-3-aryl, heteroarylb, —COOR12, —CONR12R13, CF3 or NR12R13;
- heteroarylb is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members which are, independently, N, NR12, S or O;
- wherein heteroarylb is optionally substituted with 1, 2 or 3 substituents which are, independently, alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, aryl, —(CH2)1-3-aryl, —COOR12, —CONR12R13, CF3 or NR12R13;
- R12 and R13 are, independently, H or alkyl;
- or R12 and R13 together with the nitrogen to which they are attached form a 4-, 5-, 6- or 7-membered heterocyclic ring which is saturated or unsaturated with 1 or 2 double bonds;
- R14 and R15 together with the nitrogen to which they are attached form a 4-, 5-, 6- or 7-membered heterocyclic ring which is saturated or unsaturated with 1 or 2 double bonds, and optionally is oxo substituted;
- wherein,
- when R5, R6 and R7 are absent or H, then:
- either
- R10 and R11 together form a cycloalkyl ring or a cyclic ether;
- or
- A is aryl and aryl is phenyl, biphenyl or naphthyl substituted with 1, 2 or 3 substituents which are, independently, OH, heteroaryl, arylb, —O-arylb, —(CH2)1-3-arylb, —(CH2)1-3-heteroaryl, —COOR12, —CONR12R13, or —(CH2)3—NR14R15;
- wherein,
- arylb is phenyl, biphenyl or naphthyl, wherein arylb is substituted with 1, 2 or 3 substituents which are, independently, alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, —COOR12, —CONR12R13, CF3 or NR12R13;
- and
- heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members which are, independently, N, NR12, S or O, wherein heteroaryl is substituted with 1, 2 or 3 substituents which are, independently, alkyl, alkoxy, halo, CN, aryl, morpholinyl, piperidinyl, —(CH2)1-3-aryl, heteroarylb, —COOR12, —CONR12R13, CF3 or —NR12R13;
- or
- A is heteroaryl and heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members which are, independently, N, NR12, S and O, wherein heteroaryl is substituted with 1, 2 or 3 substituents which are, independently, aryl, —(CH2)1-3-aryl, heteroarylb, —COOR12, or —CONR12R13;
- wherein,
- aryl is phenyl, biphenyl or naphthyl, wherein aryl is substituted with 1, 2 or 3 substituents which are, independently, alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, heteroaryl, arylb, —O-arylb, —(CH2)1-3-arylb, —(CH2)1-3-heteroaryl, —COOR12, —CONR12R13, —COR12R13, —(CH2)1-3—NR14R15, CF3 or —NR12R13;
- and
- heteroarylb is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members which are, independently, N, NR12, S or O, wherein heteroarylb is substituted with 1, 2 or 3 substituents which are, independently, alkyl, alkoxy, halo, CN, morpholinyl, piperidinyl, aryl, —(CH2)1-3-aryl, —COOR12, —CONR12R13, CF3 or NR12R13;
- or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof;
- wherein the disease or condition in which plasma kallikrein activity is implicated is cerebral haemorrhage, disseminated intravascular coagulation, blood coagulation during cardiopulmonary bypass surgery, or bleeding from post operative surgery.
Dependencies are inferred from the claim text.